No Panic At Newron Over Delayed Schizophrenia Drug Trial
Although the US FDA raised concerns about a rat toxicity trial, causing shares to slide, Italy's Newron believes the trial delay for schizophrenia therapy evenamide is just a blip.
Although the US FDA raised concerns about a rat toxicity trial, causing shares to slide, Italy's Newron believes the trial delay for schizophrenia therapy evenamide is just a blip.